by Antisense and RNAi therapeutics hold promise for inhibiting the expression of disease-causing genes through modulating or “silencing” messenger RNA (mRNA). Key products involve antisense oligonucleotides and RNA interference technologies that can precisely block the production of harmful proteins. The growing success of RNAi therapies to treat rare genetic conditions is driving increased interest from biopharma companies. The global Antisense & RNAi Therapeutics Market is estimated to be valued at US$6.38 Billion in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing adoption of antisense therapy to treat various diseases is a major factor propelling the growth of the global antisense and RNAi therapeutics market. For instance, the FDA has approved various antisense drugs such as Spinraza by Biogen Inc. for treating spinal muscular atrophy, Onpattro by Alnylam Pharmaceuticals for treating hereditary transthyretin-mediated amyloidosis, and Waylivra by Ionis Pharmaceuticals for treating familial chylomicronemia syndrome. These product approvals are reducing the disease burden worldwide and generating high revenue for drug manufacturers. Furthermore, increasing research activities from biopharma players for developing novel RNAi and antisense drugs for various indications including neurodegenerative diseases, cancer and genetic disorders are further augmenting the market growth.
SWOT Analysis
Strength: Antisense & RNAi Therapeutics offer targeted treatment with minimal off-target effects and have potential to treat various genetic diseases. This advantage over conventional drugs is driving their adoption.
Weakness: High development costs and lengthy clinical trials are major challenges. Delivery and stability issues need to be addressed for realizing full potential.
Opportunity: Growing R&D activities and strong pipeline offers significant growth prospects. Increasing focus on precision medicine provides opportunities to expand applications across oncology and rare diseases.
Threats: Safety concerns and possibility of immune reactions can delay approvals. Dependence on few key players increases market uncertainty.
Key Takeaways
The global Antisense & RNAi Therapeutics market analysis is expected to witness high growth. The market size is forecast to increase from US $6.38 Bn in 2024 to US $14.89 Bn by 2031, registering a CAGR of 18%.
Regional analysis
North America dominates currently due to rapid adoption of advanced therapies and strong government support for research. Asia Pacific is expected to grow at the fastest pace supported by increasing healthcare investments, expanding research facilities and rapid economic growth in China and India.
Key players
operating in the Antisense & RNAi Therapeutics are Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc., Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma. Ionis Pharmaceuticals and Alnylam Pharmaceuticals are leading players with several approved products and promising clinical pipelines.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
